Luminex Corporation and Mayo Clinic announced that they have signed a development licensing agreement that enables Mayo to provide genetic and other testing services to patients using Luminex’s xMAP® technology.
The agreement contains collaboration and licensing provisions for the inherited disorder thalassemia and also provides opportunities for additional test content creation.
“The Mayo Clinic has been a leader in the field of diagnostics for many years, paving the way to improve detection, monitoring and treatment of many medical conditions,” said Patrick J. Balthrop, president and chief executive officer of Luminex.
“We are thrilled to collaborate with Mayo to develop new genetic testing services for thalassemia and look forward to supporting additional ways our xMAP technology can be used to enhance the diagnosis and treatment of patients with other conditions.”
Thalassemia, sometimes referred to as Mediterranean anemia, is an inherited blood disorder caused by defects in the genes that make hemoglobin. Those with thalassemia have less hemoglobin and fewer red blood cells than those without the disease, which results in anemia. It is estimated that over two million people in the United States carry the genetic trait for thalassemia.
Mayo Clinic will enhance its current genetic testing services for thalassemia to include a new molecular diagnostic test based on Multiplex Ligation-dependent Probe Amplification (MLPA) and bead-based liquid micro-array technology using xMAP technology from Luminex.